SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 1107-1117

  Tian, Yu Feng ^a,b   Chen, Tzu Ju ^a   Lin, Ching Yih ^a,c   Chen, Li Tzong ^d,e,f,g   Lin, Li Ching ^a   Hsing, Chung Hsi ^a   Lee, Sung Wei ^a   Sheu, Ming Jen ^a   Lee, Hao Hsien ^a   Shiue, Yow Ling ^h   Huang, Hsuan Ying ⁱ   Pan, Hsin Yi ^a   Li, Chien Feng ^a,c,d,j   Chen, Shang Hung ^a,d,e  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

ⁱ CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^j CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

more..

Author keywords

Neoadjuvant chemoradiotherapy; Rectal cancer; SKP2

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; CASPASE 3; CASPASE 7; DOUBLE STRANDED DNA; FLUOROURACIL; S PHASE KINASE ASSOCIATED PROTEIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GRADING; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DNA STRAND BREAKAGE; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN TARGETING; RECTUM CANCER; RETROSPECTIVE STUDY; ADENOCARCINOMA; ADJUVANT THERAPY; CANCER INVASION; CELL PROLIFERATION; CHEMORADIOTHERAPY; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MORTALITY; PROGNOSIS; RECTUM TUMOR; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR RECURRENCE; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL PROLIFERATION; CHEMORADIOTHERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRAZINES; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84877133584     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0652-z     Document Type: Article

References (25)

1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40.
2. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620-5.
3. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-23.
4. National Comprehensive Cancer Network Home Page. http://www.nccn.org/. Accessed 10 Jan 2011.
5. Hyams DM, Mamounas EP, Petrelli N, Rockette H, Jones J, Wieand HS, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum. Dis Colon Rectum. 1997;40(2):131-9.
6. Valentini V, Coco C, Cellini N, Picciocchi A, Genovesi D, Mantini G, et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys. 1998;40(5):1067-75.
7. Wagman R, Minsky BD, Cohen AM, Guillem JG, Paty PP. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys. 1998;42(1):51-7.
8. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, et al. P45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol. 1999;1(4):207-14.
9. Yokoi S, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T, et al. A novel target gene, skp2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol. 2002;161(1):207-16.
10. Huang HY, Kang HY, Li CF, Eng HL, Chou SC, Lin CN, et al. Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas. Clin Cancer Res. 2006;12(2):487-98.
11. Fang FM, Chien CY, Li CF, Shiu WY, Chen CH, Huang HY. Effect of S-phase kinase-associated protein 2 expression on distant metastasis and survival in nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2009;73(1):202-7.
12. He QJ, Zeng WF, Sham JST, Xie D, Yang XW, Lin HL, et al. Recurrent genetic alterations in 26 colorectal carcinomas and 21 adenomas from Chinese patients. Cancer Genet Cytogenet. 2003;144(2):112-8.
13. Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, et al. Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol. 2010;12(5):457-67.
14. Li CF, Wang JM, Kang HY, Huang CK, Wang JW, Fang FM, et al. Characterization of gene amplification-driven skp2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics. Clin Cancer Res. 2012;18(6):1598-610.
15. Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012;149(5):1098-111.
16. Wang XC, Tian LL, Tian J, Jiang XY. Overexpression of SKP2 promotes the radiation resistance of esophageal squamous cell carcinoma. Radiat Res. 2011;177(1):52-8.
17. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
18. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, et al. Bortezomib (Velcade) induces p27kip1 expression through s-phase kinase protein 2 degradation in colorectal cancer. Cancer Res. 2008;68(9):3379-88.
19. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A. 2001;98(9):5043-8.
20. Shapira M, Ben'Izhak O, Linn S, Futerman B, Minkov I, Hershko DD. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer. 2005;103(7):1336-46.
21. Dworak OKL, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12:19-23.
22. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-96.
23. Lin CY, Tian YF, Wu LC, Chen LT, Lin LC, Hsing CH, et al. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation. J Clin Pathol. 2012;65(8):687-92.
24. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330-8.
25. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8(8):2505-11.